DASL

ProAmpac DASL’s with Design Excellence Award

Retrieved on: 
Tuesday, December 5, 2023
Packaging, Retail, Environment, Manufacturing, Sustainability, Food, Beverage, CIC, Food court, Innovation Center station, Multimedia, Innovation, DASL, Typesetting

ProAmpac , a leader in flexible packaging and material science, is proud to announce that it was honored with a 2023 American Inhouse Design Award™ for its ProActive Recyclable® RP-1000 Recyclable Paper packaging.

Key Points: 
  • ProAmpac , a leader in flexible packaging and material science, is proud to announce that it was honored with a 2023 American Inhouse Design Award™ for its ProActive Recyclable® RP-1000 Recyclable Paper packaging.
  • Hosted by Graphic Design USA (GDUSA), this award recognizes the exceptional work of ProAmpac’s in-house Design and Sample Lab (DASL) .
  • By tapping into DASL's design expertise, we help our customers elevate emerging sustainable packaging developments with brand identity and shelf appeal,” says Sal Pellingra, vice president of global package design, applications, and business development.
  • To learn more about ProAmpac’s DASL (Design and Sample Lab), email [email protected] or visit ProAmpac.com/DASL .

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022

Retrieved on: 
Tuesday, August 30, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, COVID-19, Fatigue, Safety, Pain, Ari, Food and Drug Administration, Bleeding, Precision medicine, Toxicity, ESMO, Cardiac arrest, Myocardial infarction, Birth, Congress, Urinary retention, ADT, TRK, ORR, Pulmonary embolism, DASL, Adult, Moyamoya disease, Risk, Prostate cancer, Sudden death, ESCC, Patient, Bone, Female, Dyslipidemia, Hypocalcemia, Seizure, Appetite, Death, Heart failure, Food, MCRPC, FDA, Hematuria, Diabetes, Data, Docetaxel, Hyperglycemia, Consciousness, Disease, Cancer, Pneumonia, AST, Recurrence, Fatal, Rash, Radium, Quality of life, Lists of diseases, Constipation, Immunotherapy, Febrile neutropenia, ALP, Mutation, Heart, Anemia, Bilirubin, Nivolumab, ALT, Orion Corporation, Hypertension, Pregnancy, Pharmaceutical industry, Medical imaging, EU, Bayer, ARAMIS, Radium-223

Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022.

Key Points: 
  • Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022.
  • Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments.
  • The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

Retrieved on: 
Monday, August 8, 2022
Orbis, ASCO, ADT, Cancer, DASL, Patient, AES, New Drug Application, Food, Disease, Prostate cancer, Union, Risk, Radiation, PBO, CNS, Clinician, Diagnosis, Congress, CBF, Safety, Priority review, SSE, Learning, Orion, Prostate, Traffic barrier, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, The New England Journal of Medicine, Phase, Darolutamide, Growth, Man, MCRPC, Ari, Shanda, FDA, Mortality, Veni, vidi, vici, RTOR, Recurrence, RATS, Memory, Society, OCE, Review, Central nervous system, Treatment, Docetaxel, Malignancy, CRPC, Pharmaceutical industry, Medical imaging, EU, Bayer, Survival, Incidence

Darolutamide in combination with docetaxel and ADT demonstrated a 32.5% reduction in the risk of death compared to docetaxel plus ADT.

Key Points: 
  • Darolutamide in combination with docetaxel and ADT demonstrated a 32.5% reduction in the risk of death compared to docetaxel plus ADT.
  • The compound is also being investigated in further studies across various stages of prostate cancer.
  • Ng, K., Smith, S., Shamash, J. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting.
  • Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N. Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

SRI International Announces Collaboration Agreement with Janssen

Retrieved on: 
Saturday, January 8, 2022
Janssen Pharmaceuticals, AL, Drug discovery, Artificial intelligence, Johnson & Johnson, Synchro, Education, Patient, SRI International, Organization, Synthetic jet, Automation, DASL, RSO, Janssen, Pharmaceutical industry, Fine chemical, SRI

MENLO PARK, Calif., Jan. 5, 2022 /PRNewswire/ --SRI International (SRI) today announced the company has entered into a collaboration agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points: 
  • MENLO PARK, Calif., Jan. 5, 2022 /PRNewswire/ --SRI International (SRI) today announced the company has entered into a collaboration agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • SRI International creates world-changing solutions making people safer, healthier and more productive.
  • SRI, a research center headquartered in Menlo Park, California, works primarily in advanced technology and systems, biosciences, computing and education.
  • SRI brings its innovations to the marketplace through technology licensing, spin-off ventures and new product solutions.

ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

Retrieved on: 
Friday, December 3, 2021
Patient, Senior, Man, Docetaxel, Safety, Prostate cancer, Overalls, European Union, DASL, Diagnosis, Recurrence, Cancer, Radiation, Traffic barrier, SSE, Darolutamide, Congress, Central nervous system, Malignancy, Survival, ADT, Risk, Phase, Incidence, Marketing, Ari, Union, AES, Growth, Orion, II, CNS, Disease, CRPC, Medical imaging, Pharmaceutical industry

In the ARASENS trial, darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to placebo, docetaxel and ADT.

Key Points: 
  • In the ARASENS trial, darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to placebo, docetaxel and ADT.
  • The results show that darolutamide, a compound discovered by Orions scientists, in combination with docetaxel and androgen deprivation therapy improves overall survival for patients with metastatic hormone-sensitive prostate cancer.
  • Men with metastatic hormone-sensitive prostate cancer (mHSPC) will start their treatment with hormone therapy, such as ADT, androgen receptor inhibitor (ARi) plus ADT or a combination of the chemotherapy docetaxel and ADT.
  • Despite this treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival.

Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly Increasing Overall Survival (OS) in Patients with mHSPC

Retrieved on: 
Friday, December 3, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Man, Prostate cancer, Senior, MFS, Docetaxel, Gonadotropin-releasing hormone, Death, Diagnosis, Recurrence, Malignancy, Trust, Hematuria, Risk, CYP3A4, Heart, CRPC, Birth, Orchiectomy, DASL, Cancer, OATP1B1, Pregnancy, Research, ADT, Documentation, Trial of the century, Urinary retention, SSE, Clinician, Congress, American Cancer Society, Female, Safety, Phase, Orion Corporation, Tablet, FDA, Growth, Patient, Cardiac arrest, Ageing, BCRP, AR, Pulmonary embolism, Developmental toxicity, Plasma, Group, OATP1B3, ARAMIS, Oncology, RPF, Pneumonia, Ari, Mortality, Science, AUC, Disease, Birth control, Pharmaceutical industry, Medical imaging, Vaccine, the ARASENS Trial1, the ARANOTE Trial, NUBEQA® (darolutamide), Metastatic Hormone-Sensitive Prostate Cancer, Oncology at Bayer, Bayer, THE ARASENS TRIAL1, THE ARANOTE TRIAL, NUBEQA® (DAROLUTAMIDE), METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, ONCOLOGY AT BAYER, BAYER

In the ARASENS trial, NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to docetaxel and ADT.

Key Points: 
  • In the ARASENS trial, NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to docetaxel and ADT.
  • The ARANOTE trial (NCT04736199) is a randomized, double-blind, placebo-controlled Phase III study of NUBEQA in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).
  • In the clinical study, 1,509 patients were randomized in a 2:1 ratio to receive 600 mg of NUBEQA orally twice daily or androgen deprivation therapy (ADT) alone.
  • NUBEQA (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

ProAmpac Emphasizes Sustainable Innovations at Pack Expo 2021

Retrieved on: 
Thursday, September 23, 2021
Natural Resources, Environment, Packaging, Chemicals, Plastics, Food, Beverage, Manufacturing, Retail, Forest Products, Dorado, Goal, Socially responsible investing, PRI, DASL, Solution, Innovation Center station, Intensity, Analytic, Physical, Media, Industry, Acquisition, CIC, United Nations Principles of Medical Ethics, Paper, Snack, QSR, Renewable energy, ProAmpac, Pritzker Private Capital, PROAMPAC, PRITZKER PRIVATE CAPITAL

Adam Grose states, Offering recyclable solutions today provides the industry with commercially available options to advance their sustainable product development objectives.

Key Points: 
  • Adam Grose states, Offering recyclable solutions today provides the industry with commercially available options to advance their sustainable product development objectives.
  • ProAmpac is committed to serving the world's brand owners with the most advanced materials while also making sure these materials run at-rate on existing filling and converting equipment.
  • Considered a market first, the RecycAll Freshpack sandwich skillet is an all-fiber sandwich pack with a window.
  • ProAmpacs approach to sustainability ProActive Sustainability provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals.